Hs.KRAS4b Citations (4)
Originally described in: RAS mutant collection V2.0Esposito unpublished
Articles Citing Hs.KRAS4b
| Articles |
|---|
| A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC. Sci Signal. 2019 Sep 24;12(600). pii: 12/600/eaaw8288. doi: 10.1126/scisignal.aaw8288. PubMed |
| The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer. Lee SH, Jeon Y, Kang JH, Jang H, Lee H, Kim SY. Cancers (Basel). 2020 May 28;12(6). pii: cancers12061382. doi: 10.3390/cancers12061382. PubMed |
| Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. McFall T, Stites EC. Cell Rep. 2021 Dec 14;37(11):110096. doi: 10.1016/j.celrep.2021.110096. PubMed |
| RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome-associated cardiac hypertrophy. Cuevas-Navarro A, Wagner M, Van R, Swain M, Mo S, Columbus J, Allison MR, Cheng A, Messing S, Turbyville TJ, Simanshu DK, Sale MJ, McCormick F, Stephen AG, Castel P. Sci Adv. 2023 Jul 14;9(28):eadf4766. doi: 10.1126/sciadv.adf4766. Epub 2023 Jul 14. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.